Clinical Trial Update: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Nanrilkefusp alfa alone and with pembrolizumab in adults with advanced or metastatic solid tumors; the study (NCT04234113) was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Squamous Cell Carcinoma of the Skin
• Thyroid Cancer

Drugs mentioned

• Nanrilkefusp Alfa (nanrilkefusp alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: SOTIO Biotech AG | Conditions: Thyroid Cancer, Renal Cell Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2026-03-27